Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
Quantify Research, Stockholm, Sweden.
Alzheimers Dement. 2023 Feb;19(2):658-670. doi: 10.1002/alz.12694. Epub 2022 Jun 2.
Global estimates on numbers of persons in early stages of Alzheimer's disease (AD), including prodromal and preclinical, are lacking, yet are needed to inform policy decisions on preventive measures and planning for future therapies targeting AD pathology.
We synthesized the literature on prevalence across the AD continuum and derived a model estimating the number of persons, stratified by 5-year age groups, sex, and disease stage (AD dementia, prodromal AD, and preclinical AD).
The global number of persons with AD dementia, prodromal AD, and preclinical AD were estimated at 32, 69, and 315 million, respectively. Together they constituted 416 million across the AD continuum, or 22% of all persons aged 50 and above.
Considering predementia stages, the number of persons with AD is much larger than conveyed in available literature. Our estimates are uncertain, especially for predementia stages in low- and middle-income regions where biomarker studies are missing.
目前缺乏关于阿尔茨海默病（AD）早期阶段（包括前驱期和临床前阶段）人数的全球估计数，但为了为针对 AD 病理的预防措施和未来治疗方法的决策提供信息，这些估计数是必要的。
我们综合了关于 AD 连续体患病率的文献，并建立了一个模型，对按 5 岁年龄组、性别和疾病阶段（AD 痴呆、前驱期 AD 和临床前 AD）分层的人数进行了估计。
全球 AD 痴呆、前驱期 AD 和临床前 AD 患者的人数分别估计为 3200 万、690 万和 3.15 亿。它们共同构成了 AD 连续体中的 4.16 亿人，占所有 50 岁及以上人群的 22%。
考虑到前驱期阶段，AD 患者的人数远远大于现有文献所传达的数量。我们的估计数存在不确定性，特别是在缺乏生物标志物研究的中低收入地区的前驱期阶段。
